Panteha Eshtiaghi1, Leslie Ann Sadownik2,3. 1. Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of British Columbia. 3. BC Centre for Vulvar Health, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVE: The aim of the study was to summarize and review the evidence for the efficacy and safety of adipose-derived stem cells (ADSCs) and platelet-rich plasma (PRP) for the treatment of vulvar lichen sclerosus (LS). MATERIALS AND METHODS: PubMed/MEDLINE, Ovid, Web of Science, and clinicaltrials.gov were searched from inception up to May 7, 2018. RESULTS: Seven observational studies were identified, with a total of 98 patients. Both ADSCs and PRP were reported to improve symptoms, quality of life measures, as well as clinical and histological signs of vulvar LS. There is a strong risk of biased estimates of treatment effect. CONCLUSIONS: Current evidence is weak for ADSCs and/or PRP as treatment for vulvar LS. Further research is needed before recommending this therapy.
OBJECTIVE: The aim of the study was to summarize and review the evidence for the efficacy and safety of adipose-derived stem cells (ADSCs) and platelet-rich plasma (PRP) for the treatment of vulvar lichen sclerosus (LS). MATERIALS AND METHODS: PubMed/MEDLINE, Ovid, Web of Science, and clinicaltrials.gov were searched from inception up to May 7, 2018. RESULTS: Seven observational studies were identified, with a total of 98 patients. Both ADSCs and PRP were reported to improve symptoms, quality of life measures, as well as clinical and histological signs of vulvar LS. There is a strong risk of biased estimates of treatment effect. CONCLUSIONS: Current evidence is weak for ADSCs and/or PRP as treatment for vulvar LS. Further research is needed before recommending this therapy.
Authors: Nanouk van der Sluis; Esther C A H Scheers; Guido Krenning; Berend van der Lei; Maaike H M Oonk; Joris A van Dongen Journal: Exp Dermatol Date: 2022-03-16 Impact factor: 4.511